Drilldown: Medicines

None (3) · Spironolactone (1) · Vardenafil (1)

Aldactone, CaroSpir (1) · Belsomra (1) · Dayvigo (1) · Levitra, Staxyn (1) · Quviviq (1)

Dual orexin receptor antagonist (DORA) (3) · PDE5 Inhibitor (1) · the first approved (1) · [[:Category:Aldosterone_antagonists|Mineralocorticoid (aldosterone) receptor antagonist]] (1) · [[:Category:Antiandrogens|Antiandrogen]] (1) · [[:Category:Potassium-sparing_diuretics|Potassium-sparing diuretic]] (1)

None (2) · Competitive antagonist at OX1R and OX2R. Faster receptor association/dissociation kinetics than suvorexant (~16 sec dissociation vs ~57 sec) hypothesized to support sleep onset, with sufficient duration for maintenance. (1) · Competitive antagonist at OX1R and OX2R. First-in-class DORA. Receptor dissociation slower than lemborexant or daridorexant. (1) · Selective inhibitor of PDE5. Slightly higher PDE5/PDE6 selectivity vs sildenafil (less visual side effect) but more PDE1 cross-activity (occasional QT effects at high doses). (1)

Insomnia (sleep onset and/or maintenance) in adults (FDA-approved August 2014). Also studied for insomnia in mild-moderate Alzheimer disease. (1) · Insomnia (sleep onset and/or maintenance) in adults (FDA-approved Dec 2019) (1) · Insomnia (sleep onset and/or sleep maintenance) in adults (FDA-approved Jan 2022) (1) · '"`UNIQ--vote-0000034F-QINU`"', '"`UNIQ--vote-00000350-QINU`"', '"`UNIQ--vote-00000351-QINU`"', '"`UNIQ--vote-00000352-QINU`"', '"`UNIQ--vote-00000353-QINU`"' (1) · '"`UNIQ--vote-00000669-QINU`"' (1)

10 mg PO 30 min before bedtime (with ≥7 hours of sleep planned) (1) · 10 mg ~1 h before sexual activity (1) · 25 mg PO at bedtime (no titration); may increase to 50 mg if 25 mg inadequate (1) · 25 mg PO once daily for HFrEF and primary aldosteronism; up to 100 mg/d for ascites; 50-200 mg/d for hirsutism (1) · 5 mg PO at bedtime; may increase to 10 mg if inadequate (1)

2.5, 5, 10, 20 mg tabs (Levitra); 10 mg ODT (Staxyn) (1) · 25 mg, 50 mg tablets (1) · 25 mg, 50 mg, 100 mg tablets; 25 mg/5 mL oral suspension (CaroSpir) (1) · 5 mg, 10 mg tablets (1) · 5 mg, 10 mg, 15 mg, 20 mg tablets (1)

10 mg/d (1) · 20 mg/d (2) · 400 mg/d (acute primary aldosteronism diagnosis); 100-200 mg/d typical chronic (1) · 50 mg/d (1)

Oral (5)

None · Hours · 30-60 minutes · 1-2 hours · ~30 min · LDL lowering at 2 weeks, max by 4 weeks · ~1 hour · 15-30 minutes · 15–30 min · 1–2 h · 30–60 min · Antidepressant effect emerges over 1-2 weeks · BP and symptomatic LUTS improvement within 1-2 weeks · BP effect within 1-2 weeks · Clinical improvement within 24-72 hours · Days · Motor improvement over days at therapeutic dose · Over weeks · Postprandial glucose effect within days; HbA1c by 12 weeks · Sleep effect from first dose; antidepressant effect over 1-4 weeks

Other values:

Search

4–5 h (1) · Variable; biologically active metabolite carries effect beyond plasma half-life (1) · ~7-8 hours (3)

1.4 hours (parent); 13-24 hours for active metabolite canrenone'"`UNIQ--ref-00000354-QINU`"' (1) · 4–5 h (1) · ~12 hours (1) · ~17-19 hours (longer than daridorexant) (1) · ~8 hours (shorter than suvorexant and lemborexant) (1)

~15% (extensive hepatic first-pass) (1) · ~44% (1) · ~62% (1) · ~70% (oral; bioavailability and absorption are improved with food)'"`UNIQ--ref-00000355-QINU`"' (1) · ~82% (1)

Avoid in pregnancy; antiandrogen effects can feminize a male fetus.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Category B (1) · Limited data; avoid (3)

Rx, Schedule IV (US) (3) · Rx-only in US (1) · [[USLegal:Prescription only|Rx-only]] in US (1)